Merck & Co., Inc. (NYSE:MRK) Receives $135.50 Average PT from Brokerages

Shares of Merck & Co., Inc. (NYSE:MRK) have been given a consensus recommendation of “Moderate Buy” by the twenty-three analysts that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $144.10.

MRK has been the topic of a number of research reports. Morgan Stanley raised Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $116.00 to $179.00 in a report on Thursday. UBS Group upped their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday. Argus increased their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Wells Fargo & Company increased their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $152.43 on Monday. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $154.49. The company has a fifty day moving average of $128.09 and a 200-day moving average of $121.29. The company has a market capitalization of $376.07 billion, a P/E ratio of 121.94, a P/E/G ratio of 6.40 and a beta of 0.19. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Insider Buying and Selling

In other news, EVP Richard R. Deluca sold 20,784 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the transaction, the executive vice president directly owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. This represents a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last 90 days. Insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter valued at $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the 4th quarter worth $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. in the 4th quarter worth $26,000. High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $31,000. 76.07% of the stock is currently owned by institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.